Fact CheckerSign in

NCT05988697Not yet recruiting

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation

Source: ClinicalTrials.gov · Last updated 12 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
36 (estimated)
First submitted
4 Aug 2023
Start date
1 Nov 2023
Primary completion date
1 Sept 2026
Lead sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Diseases
Lung cancer
NCT number
NCT05988697

What you commit to

  • Study type: Observational
  • Planned participants: 36
  • From 1 Nov 2023 to the primary completion date, 1 Sept 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • The patient is currently receiving other anticoagulant therapy;
  • The patient was previously treated with systemic anti-NSCLC;

Lab values

  • The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.

Other

  • The patient had contraindications for dalafenib or trametinib and aspirin use;
  • Patients who refused follow-up visits;

Who the study is looking for

  • Inoperable stage IIIB-IV patients with non-small cell lung cancer;
  • BRAF V600E mutation;
  • Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;
  • ECOG PS 0/1;
  • The diameter of the primary lesion should be at least 1cm;
  • Previous or current aspirin treatment was allowed

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.